Pseudoephedrine accumulation in renal failure - PubMed

Case Reports

Pseudoephedrine accumulation in renal failure

D A Sica et al. Am J Med Sci. 1989 Oct.

Abstract

Neuropsychiatric complications, such as metabolic encephalopathy, are common occurrences in end-stage renal disease (ESRD) patients. Frequently, metabolic encephalopathy develops in relationship to the multiple pharmacologic therapies routinely employed in this population. Such polypharmacy often leads to adverse drug reactions, drug-drug interactions, or dosage error. In this regard, over-the-counter (OTC) medications are commonly perceived as being "somewhat benign" when, in fact, their potential for adverse effect may be significant. The authors describe the course of a 64-year-old hemodialysis patient who became intoxicated on conventional doses of pseudoephedrine only to regain neurologic integrity upon discontinuation of the medication.

Similar articles

• Pseudoephedrine toxicity in renal failure.

  Lyon CC, Turney JH. Lyon CC, et al. Br J Clin Pract. 1996 Oct-Nov;50(7):396-7. Br J Clin Pract. 1996. PMID: 9015914

• [Myoclonia caused by a combination of triprolidine, pseudoephedrine and paracetamol].

  Jacquesson M, Saudeau D, Pantin B, Girard JJ, Groussin P. Jacquesson M, et al. Nouv Presse Med. 1982 Jun 26;11(30):2298-9. Nouv Presse Med. 1982. PMID: 7110997 French. No abstract available.

• Encephalopathy in chronic renal failure responsive to deferoxamine therapy. Another manifestation of aluminum neurotoxicity.

  Sprague SM, Corwin HL, Wilson RS, Mayor GH, Tanner CM. Sprague SM, et al. Arch Intern Med. 1986 Oct;146(10):2063-4. Arch Intern Med. 1986. PMID: 3767553

• Emergency medicine evaluation and management of the end stage renal disease patient.

  Long B, Koyfman A, Lee CM. Long B, et al. Am J Emerg Med. 2017 Dec;35(12):1946-1955. doi: 10.1016/j.ajem.2017.09.002. Epub 2017 Sep 5. Am J Emerg Med. 2017. PMID: 28893450 Review.

• Myoclonus and Altered Mental Status Induced by Single Dose of Gabapentin in a Patient With End-Stage Renal Disease: A Case Report and Literature Review.

  Yeddi A, Adam O, Khalid M, Benjaram S, Abu-Heija A, Abdallah MA, Shah P. Yeddi A, et al. Am J Ther. 2019 Nov/Dec;26(6):e768-e770. doi: 10.1097/MJT.0000000000000942. Am J Ther. 2019. PMID: 30839320 Review. No abstract available.

Cited by

• Drug-induced movement disorders.

  Jiménez-Jiménez FJ, García-Ruiz PJ, Molina JA. Jiménez-Jiménez FJ, et al. Drug Saf. 1997 Mar;16(3):180-204. doi: 10.2165/00002018-199716030-00004. Drug Saf. 1997. PMID: 9098656 Review.

• Drug-induced myoclonus: frequency, mechanisms and management.

  Jiménez-Jiménez FJ, Puertas I, de Toledo-Heras M. Jiménez-Jiménez FJ, et al. CNS Drugs. 2004;18(2):93-104. doi: 10.2165/00023210-200418020-00003. CNS Drugs. 2004. PMID: 14728056 Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science
  • Ovid Technologies, Inc.

• Medical

  • MedlinePlus Health Information